Literature DB >> 9115968

Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations.

M J Calasanz1, J C Cigudosa, M D Odero, C Ferreira, M T Ardanaz, A Fraile, J L Carrasco, F Solé, B Cuesta, A Gullón.   

Abstract

Cytogenetic analysis of unstimulated short-term bone marrow cell cultures was performed on 280 patients with multiple myeloma and related disorders. In 65% of the cases, an additional short term B-cell stimulated culture was also examined. Chromosomally abnormal clones were found in 31% of the patients, 15% in Waldenström macroglobulinemia. 25% in monoclonal gammopathies, 33% in multiple myeloma, and 50% in plasma cell leukemia. Three primary chromosomal breakpoints were recurrently involved: 14q32, 16q22, and 22q11. Structural rearrangements of chromosome 1 were the most frequent (26% of the abnormal cases), but always as a secondary change. Rearrangements of band 14q32 were found in 22% of the abnormal cases. Among the multiple myeloma patients who showed an abnormal karyotype, 33 (46%) were hyperdiploid, most frequently, with 52-56 chromosomes, 29 patients (40%) were pseudodiploid, and the remaining 12 cases (14%) were hypodiploid. A highly significant relation was observed between the presence of an abnormal karyotype and the following clinical parameters: stage III (P = 0.0001), bone marrow plasma cell infiltration greater than 30% (P = 0.0001), presence of bone lesions (P = 0.0009), and beta 2-microglobulin levels greater than 4 mg/L (P = 0.0001).

Entities:  

Mesh:

Year:  1997        PMID: 9115968

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  22 in total

1.  RNAs in the sera of Persian Gulf War veterans have segments homologous to chromosome 22q11.2.

Authors:  H B Urnovitz; J J Tuite; J M Higashida; W H Murphy
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

Review 2.  Genomics in multiple myeloma.

Authors:  Nikhil C Munshi; Hervé Avet-Loiseau
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

3.  Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

Authors:  Benjamin Hebraud; Florence Magrangeas; Alice Cleynen; Valerie Lauwers-Cances; Marie-Lorraine Chretien; Cyrille Hulin; Xavier Leleu; Edwige Yon; Gerald Marit; Lionel Karlin; Murielle Roussel; Anne-Marie Stoppa; Karim Belhadj; Laurent Voillat; Laurent Garderet; Margaret Macro; Denis Caillot; Mohamad Mohty; Thierry Facon; Philippe Moreau; Michel Attal; Nikhil Munshi; Jill Corre; Stephane Minvielle; Herve Avet-Loiseau
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

4.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Authors:  Y Shou; M L Martelli; A Gabrea; Y Qi; L A Brents; A Roschke; G Dewald; I R Kirsch; P L Bergsagel; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

5.  Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases.

Authors:  Cigdem Aydin; Turgay Ulas; Ceren Hangul; Orhan Kemal Yucel; Utku Iltar; Ozan Salim; Deniz Ekinci; Sibel Berker Karauzum
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-25       Impact factor: 0.900

Review 6.  Genetics of multiple myeloma: another heterogeneity level?

Authors:  Jill Corre; Nikhil Munshi; Hervé Avet-Loiseau
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

7.  Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

Authors:  Hervé Avet-Loiseau; Cyrille Hulin; Loic Campion; Philippe Rodon; Gerald Marit; Michel Attal; Bruno Royer; Mamoun Dib; Laurent Voillat; Didier Bouscary; Denis Caillot; Marc Wetterwald; Brigitte Pegourie; Gerard Lepeu; Bernadette Corront; Lionel Karlin; Anne-Marie Stoppa; Jean-Gabriel Fuzibet; Xavier Delbrel; Francois Guilhot; Brigitte Kolb; Olivier Decaux; Thierry Lamy; Laurent Garderet; Olivier Allangba; Francois Lifermann; Bruno Anglaret; Philippe Moreau; Jean-Luc Harousseau; Thierry Facon
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

8.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

Authors:  Wen Zhou; Ye Yang; Jiliang Xia; He Wang; Mohamed E Salama; Wei Xiong; Hongwei Xu; Shashirekha Shetty; Tiehua Chen; Zhaoyang Zeng; Lei Shi; Maurizio Zangari; Rodney Miles; David Bearss; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Cell       Date:  2013-01-14       Impact factor: 31.743

9.  Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.

Authors:  Scott Van Wier; Esteban Braggio; Angela Baker; Gregory Ahmann; Joan Levy; John D Carpten; Rafael Fonseca
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.

Authors:  Madoka Takimoto; Kohei Ogawa; Yo Kato; Tasuku Saito; Takao Suzuki; Michiko Irei; Yasushi Shibuya; Yoshinori Suzuki; Masayuki Kato; Yasuyuki Inoue; Masatomo Takahashi; Hiroki Sugimori; Ikuo Miura
Journal:  Int J Hematol       Date:  2008-02-16       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.